Fate Therapeutics Inc. (NASDAQ:FATE) rose 4.7% during mid-day trading on Monday . The company traded as high as $2.70 and last traded at $2.68, with a volume of 122,649 shares traded. The stock had previously closed at $2.56.

FATE has been the subject of a number of recent research reports. HC Wainwright began coverage on shares of Fate Therapeutics in a report on Thursday, July 28th. They issued a “buy” rating and a $9.00 price objective for the company. BMO Capital Markets reissued an “outperform” rating and set a $4.00 target price on shares of Fate Therapeutics in a research report on Tuesday, June 21st. Zacks Investment Research raised shares of Fate Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research report on Thursday, August 11th. Leerink Swann reissued an “outperform” rating and set a $4.00 target price on shares of Fate Therapeutics in a research report on Tuesday, June 21st. Finally, Wells Fargo & Co. reissued a “buy” rating on shares of Fate Therapeutics in a research report on Tuesday, May 10th. Eight investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $6.29.

The stock’s market capitalization is $77.15 million. The firm has a 50-day moving average price of $1.96 and a 200-day moving average price of $1.85.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.03. The company had revenue of $1.03 million for the quarter, compared to analyst estimates of $1.02 million. On average, equities research analysts expect that Fate Therapeutics Inc. will post ($1.12) earnings per share for the current year.

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.